N-Phosphonacetyl-L-aspartic acid
-
N-Phosphonacetyl-L-aspartic acid
structure -
-
CAS No:
51321-79-0
-
Formula:
C6H10NO8P
-
Chemical Name:
N-Phosphonacetyl-L-aspartic acid
-
Synonyms:
L-Aspartic acid,N-(2-phosphonoacetyl)-;L-Aspartic acid,N-(phosphonoacetyl)-;N-(2-Phosphonoacetyl)-L-aspartic acid;N-Phosphonacetyl-L-aspartic acid;PALA;NSC 224131;N-(Phosphonoacetyl)-L-aspartic acid;Phosphonoacetyl-L-aspartic acid;Sparfosic acid;NCI 224131;(2S)-2-[(2-Phosphonoacetyl)amino]butanedioic acid;(2S)-2-(2-Phosphonoacetamido)butanedioic acid;755040-87-0
-
CAS No:
Description
Sparfosic acid is a solid. This compound belongs to the n-acyl-alpha amino acids. These are compounds containing an alpha amino acid which bears an acyl group at the terminal nitrogen atom. This substance is known to target aspartate carbamoyltransferase catalytic chain and CAD protein.|Sparfosic Acid is a stable transition state analogue for an aspartate transcarbamylase-catalyzed reaction with antineoplastic activity. Sparfosic acid is a stable transition analogue of the activated complex for the reaction catalyzed by aspartate transcarbamylase, the first step in the pyrimidine biosynthetic pathway. This agent inhibits de novo pyrimidine biosynthesis and increases the extent to which fluorouracil metabolites are incorporated into RNA.
N-Phosphonacetyl-L-aspartic acid Basic Attributes
255.12 g/mol
255.12
78QVZ7RG8L
DTXSID80199325
C1398
Safety Information
Bulk: The compound is very stable as the bulk drug. The bulk material is hygroscopic; protect from moisture when storing. Solution: The compound is very stable in aqueous solution (qualitative). PALA (1mg/mL) is chemically stable for at least 2 weeks at room temperature in aqueous solution.
Drug Information
Antimetabolites that are useful in cancer chemotherapy. (See all compounds classified as Antimetabolites, Antineoplastic.)|Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. (See all compounds classified as Antiviral Agents.)|Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)
l-aspartic acid, n-(2-phosphonoacetyl)-
Computed Properties
Molecular Weight:255.12
XLogP3:-3.1
Hydrogen Bond Donor Count:5
Hydrogen Bond Acceptor Count:8
Rotatable Bond Count:6
Exact Mass:255.01440327
Monoisotopic Mass:255.01440327
Topological Polar Surface Area:161
Heavy Atom Count:16
Complexity:346
Defined Atom Stereocenter Count:1
Covalently-Bonded Unit Count:1
Compound Is Canonicalized:Yes
Learn More Other Chemicals
-
3,5-DIBROMO-2-[[[(3,5-DINITROBENZOYL)AMINO]THIOXOMETHYL]AMINO]-BENZOIC ACID
535965-38-9
-
3,5-DIBROMO-2-[[[[(2-CHLOROPHENOXY)ACETYL]AMINO]THIOXOMETHYL]AMINO]-BENZOIC ACID
532386-89-3
-
3,5-DIBROMO-2-[[[(4-METHYL-3-NITROBENZOYL)AMINO]THIOXOMETHYL]AMINO]-BENZOIC ACID
532943-48-9
-
3,5-DIBROMO-2-[[[[3-(2-FURANYL)-1-OXO-2-PROPENYL]AMINO]THIOXOMETHYL]AMINO]-BENZOIC ACID Formula
586392-09-8
-
3,5-DIBROMO-2-[[[[(2-METHYLPHENOXY)ACETYL]AMINO]THIOXOMETHYL]AMINO]-BENZOIC ACID Formula
531548-30-8
-
2-(1,8-dibromo-16,18-dioxo-17-azapentacyclo[6.6.5.0~2,7~.0~9,14~.0~15,19~]nonadeca-2,4,6,9,11,13-hexaen-17-yl)benzoic acid Formula
333340-54-8
-
3,5-DIBROMO-2-[[[[3-(PHENOXYMETHYL)BENZOYL]AMINO]THIOXOMETHYL]AMINO]-BENZOIC ACID Structure
586393-79-5
-
3,5-DIBROMO-2-[[[(4-CHLOROBENZOYL)AMINO]THIOXOMETHYL]AMINO]-BENZOIC ACID Structure
531530-32-2
-
What is 2-Cyclopentyl-3-(2,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-oxo-4-isoquinolinecarboxylic acid
400073-92-9
-
What is 9-Octadecenoic acid (9Z)-, compd. with N,N-dimethylcyclohexanamine (1:1)
65122-23-8
Request for Quotation